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Elizabeth Henderson, MD; Imad Ikhwan, MD; Dharti Patel, MD; Monicka Felix, MD; Salman Muddassir, MD; Vikas Malholtra, MD

Introduction

Imaging

The immune checkpoint inhibitors, including anti-programmed cell death-1
protein (PD1) monoclonal antibodies nivolumab (Nivo) has been used to treat
advanced malignant melanoma and several malignancies including recurrent or
metastatic squamous cell carcinoma of the head and neck (SCCHN), Metastatic
Non-Small Cell Lung Cancer, advanced RCC. PD1 inhibitor
Despite the clinical efficacy of Nivolumab, autoimmune related side effects
including myasthenia Gravis has been reported, The underlying mechanism of
MG is still unclear. A recent case report introduced myasthenia gravis in a patient
with RCC. We are reporting the case of a patient with no pre-existing
myasthenia gravis (MG) in whom nivolumab was administered and developed
MG related side effect complication

Discussion
Opdivo is an anti-monoclonal antibody, that targets the anti PD-1 receptor, which
creates an anti tumor response. It has been known to be efficacious against
melanoma, and other cancers such as recurrent or metastatic squamous cell
carcinoma of the head and neck (SCCHN), Metastatic Non-Small Cell Lung Cancer,
advanced RCC.Common side effects that are known from this drug are respiratory
(17.3%), musculoskeletal (15.2%), neurological (11.5%), ocular (5.7%),
cardiac(3.6%), and hematological (.7%).

•

Background
The 61 year-old male with active melanoma undergoing treatment with
Nivolumab developed myasthenia-like symptoms following his third
round of treatment. The immunotherapy was immediately discontinued
and started on steroids by his oncologist. The patient’s symptoms did
not improve and he was subsequently admitted to the hospital where his
condition further deteriorated. He was treated with IV solumedrol,
pyridostigmine, and IVIG. The patient still did not respond to these
treatment and was treated with plasmapheresis.

Conclusions

This case illustrates the importance of early recognition and appropriate
management of immune related adverse events with immunotherapy. This
patient had early recognition and was given proper treatment, however still
expired as a result of complications secondary to Nivolumab-induced
myasthenia gravis.
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